Zymeworks said on Friday Roche has gained rights to develop and ​commercialize its experimental lung cancer drug ‌under a global licensing deal worth up to $813 million.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in